Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
15000 participants
OBSERVATIONAL
2023-07-14
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A (Retrospective):
All consecutive patients entered in the ROC platform from the start of platform activation (November 2018) until the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) will be enrolled. The retrospective cohort will be made by more than 40000 patients already included in the platform and entered a GOM path
Data collection (retrospective)
Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
Cohort B (Prospective):
All consecutive patients who enter in the ROC platform as for clinical practice from the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients).
Data collection (prospective)
Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection (retrospective)
Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
Data collection (prospective)
Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* registration in the ROC platform
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Naples
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandro Pignata, M.D.
Role: PRINCIPAL_INVESTIGATOR
IRCCS I.N.T. "G. Pascale"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A.O. Moscati
Avellino, Avellino, Italy
Asl Avellino
Avellino, Avellino, Italy
A.O. Rummo
Benevento, Benevento, Italy
Asl Benevento
Benevento, Benevento, Italy
Asl Caserta
Caserta, Caserta, Italy
A.O. S.Anna S. Sebastiano
Caserta, Caserta, Italy
Asl Napoli 2 Nord
Casavatore, Napoli, Italy
Asl Napoli 3 Sud
Ercolano, Napoli, Italy
A.O. Cardarelli
Napoli, Napoli, Italy
A.O. Dei Colli
Napoli, Napoli, Italy
Federico II
Napoli, Napoli, Italy
I.N.T. Pascale
Napoli, Napoli, Italy
A.O.U. Luigi Vanvitelli
Napoli, Napoli, Italy
Asl Napoli 1 Centro
Napoli, Napoli, Italy
Ospedale del Mare
Napoli, Napoli, Italy
Asl Salerno
Salerno, Salerno, Italy
A.O.U. Ruggi
Salerno, Salerno, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cesare Gridelli, M.D.
Role: primary
Giuseppe Genua, M.D.
Role: primary
Antonio Grimaldi, M.D.
Role: primary
Elena Fossi, M.D.
Role: primary
Antonella Guida, M.D.
Role: primary
Michele Orditura, M.D.
Role: primary
Filomena Sibilio, M.D.
Role: primary
Mario Fusco, M.D.
Role: primary
Ferdinando Riccardi, M.D.
Role: primary
Vincenzo Montesarchio, M.D.
Role: primary
Sabino De Placido, M.D.
Role: primary
Sandro Pignata, M.D.
Role: primary
Fortunato Ciardiello, M.D.
Role: primary
Tiziana Spinosa, M.D.
Role: primary
Bruno Daniele, M.D.
Role: primary
Giuseppe Di Lorenzo, M.D.
Role: primary
Stefano Pepe, M.D.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Porciello G, Di Lauro T, Luongo A, Coluccia S, Prete M, Abbadessa L, Coppola E, Di Martino A, Mozzillo AL, Racca E, Piccirillo A, Di Giacomo V, Fontana M, D'Amico M, Palumbo E, Vitale S, D'Errico D, Turra V, Parascandolo I, Stallone T, Augustin LSA, Crispo A, Celentano E, Pignata S. Optimizing Nutritional Care with Machine Learning: Identifying Sarcopenia Risk Through Body Composition Parameters in Cancer Patients-Insights from the NUTritional and Sarcopenia RIsk SCREENing Project (NUTRISCREEN). Nutrients. 2025 Apr 18;17(8):1376. doi: 10.3390/nu17081376.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6/23 oss
Identifier Type: OTHER
Identifier Source: secondary_id
ONCOCAMP
Identifier Type: -
Identifier Source: org_study_id